0001104659-24-090984.txt : 20240819 0001104659-24-090984.hdr.sgml : 20240819 20240819201428 ACCESSION NUMBER: 0001104659-24-090984 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240815 FILED AS OF DATE: 20240819 DATE AS OF CHANGE: 20240819 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ban Randy CENTRAL INDEX KEY: 0001737127 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38468 FILM NUMBER: 241222344 MAIL ADDRESS: STREET 1: C/O INSPIRE MEDICAL SYSTEMS, INC. STREET 2: 9700 63RD AVENUE NORTH, SUITE 200 CITY: MAPLE GROVE STATE: MN ZIP: 55369 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inspire Medical Systems, Inc. CENTRAL INDEX KEY: 0001609550 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 261377674 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 BUSINESS PHONE: 763-957-5037 MAIL ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 4 1 tm2422088-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-08-15 0 0001609550 Inspire Medical Systems, Inc. INSP 0001737127 Ban Randy C/O INSPIRE MEDICAL SYSTEMS, INC. 5500 WAYZATA BLVD., SUITE 1600 GOLDEN VALLEY MN 55416 0 1 0 0 Chief Commercial Officer 1 Common Stock 2024-08-15 4 M 0 16139 42.15 A 19195 D Common Stock 2024-08-15 4 S 0 776 189.06 D 18419 D Common Stock 2024-08-15 4 S 0 1659 190.20 D 16760 D Common Stock 2024-08-15 4 S 0 2072 191.92 D 14688 D Common Stock 2024-08-15 4 S 0 1150 192.60 D 13538 D Common Stock 2024-08-15 4 S 0 8132 193.92 D 5406 D Common Stock 2024-08-15 4 S 0 2350 194.91 D 3056 D Common Stock 2024-08-16 4 M 0 4861 42.15 A 7917 D Common Stock 2024-08-16 4 S 0 900 187.10 D 7017 D Common Stock 2024-08-16 4 S 0 3066 188.66 D 3951 D Common Stock 2024-08-16 4 S 0 895 189.64 D 3056 D Common Stock 167 I By son Common Stock 166 I By daughter Stock Option (Right to Buy) 42.15 2024-08-15 4 M 0 16139 0.00 D 2028-12-18 Common Stock 16139 4861 D Stock Option (Right to Buy) 42.15 2024-08-16 4 M 0 4861 0.00 D 2028-12-18 Common Stock 4861 0 D Includes 27 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan since the Reporting Person's Form 4 dated February 27, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.995 to $189.285. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.08 to $190.845. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.225 to $192.18. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.26 to $193.22. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.4 to $194.32. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.81 to $195.15. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.90 to $187.71. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.255 to $189.24. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote . The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.26 to $189.855. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option is fully vested and exercisable. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. /s/ Bryan Phillips, Attorney-in-Fact for Randy Ban 2024-08-19